Does intensity modulation improve healthy tissue sparing in stereotactic radiosurgery of arteriovenous malformation
B. G. Clark(BC Cancer Agency), Karen Goddard(BC Cancer Agency), E. Vollans(BC Cancer Agency), Ruichong Ma(John Radcliffe Hospital), A. Lee, Brian Toyota(University of British Columbia), Michael McKenzie(Provincial Health Services Authority), Sara Erridge(The University of Texas MD Anderson Cancer Center), James L. Robar(BC Cancer Agency)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2004
Cited by 0
Related Papers
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319